DrugBiological
Netakimab clinical trials
How studies write it
Studies that test it under each name
Name
- Netakimab
- 3
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses netakimab is read from its arms, and is right about nine times in ten.
Testing it · 3
- To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3SPH-BIOCAD (HK) LimitedNCT07008547Written as Netakimab
- Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3BiocadNCT06640517Written as Netakimab
- Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing SpondylitisCompletedPhase 3SPH-BIOCAD (HK) LimitedNCT07277179Written as Netakimab
Codes
What other systems call netakimab · ClinicalTrials.gg INT001688
- MeSH (NLM) C000718740netakimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D3IAG45DAKNETAKIMABConfirmed FDA, NLM
- NCI Thesaurus C175830NetakimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718740 | netakimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D3IAG45DAK | NETAKIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C175830 | Netakimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.